Related Experiment Video
Updated: Feb 19, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy
Ting Sun1, Haibin Wu1, Yanyan Li1
1Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Abstract:
Glioma stem cells, which are sub-populations of tumor cells, are responsible for resistant responses to radiotherapy and chemotherapy after surgery. Targeting resistant glioma stem cell sub-populations might present a novel means to prevent tumor recurrence. Due to the high expression of transferrin receptors at the surface of brain capillary endothelial and tumor cells, especially glioma stem cells, targeting the transferrin receptor system provides an avenue for the entry of drug molecules into the brain. Nanoparticles that target glioma stem cell sub-populations, conjugate transferrin and encapsulate temozolomide, were developed as a potential therapeutic strategy to evaluate their effectiveness at damaging tumor cells. Nanoparticles were highly effective at penetrating the blood-brain barrier and delivering a high therapeutic dose of temozolomide. This effective means of delivery provoked enhanced cytotoxicity against glioma cells, and especially against glioma stem cells. The targeting transferrin receptor nanoparticles display an inherent capacity for a highly therapeutic approach in targeting glioma stem cells and non-stem cells tumors. In addition, transferrin nanoparticles encapsulating temozolomide have the potential of a promising anti-tumor strategy against glioma of the O6-methylguanine-DNA-methyltransferase gene promoter methylation.
Insights
Targeting glioma stem cells with transferrin receptor-conjugated nanoparticles delivering temozolomide effectively crosses the blood-brain barrier, enhancing tumor cell death and offering a promising anti-glioma strategy.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Drug Delivery
Background:
- Glioma stem cells (GSCs) drive tumor recurrence and treatment resistance.
- Targeting GSCs is crucial for effective glioma therapy.
- Transferrin receptors are upregulated on GSCs, presenting a therapeutic target.
Purpose of the Study:
- To develop and evaluate transferrin receptor-targeted nanoparticles encapsulating temozolomide (TMZ) for glioma treatment.
- To assess the nanoparticles' efficacy in penetrating the blood-brain barrier (BBB) and delivering therapeutic payloads.
- To determine the cytotoxic effects of targeted nanoparticles on GSCs and non-stem glioma cells.
Main Methods:
- Development of transferrin-conjugated nanoparticles encapsulating temozolomide.
- Evaluation of nanoparticle penetration across the blood-brain barrier.
- Assessment of cytotoxicity against glioma cells and glioma stem cells in vitro.
- Analysis of therapeutic potential against O6-methylguanine-DNA-methyltransferase (MGMT) gene promoter methylated gliomas.
Main Results:
- Nanoparticles demonstrated high efficiency in crossing the blood-brain barrier.
- Effective delivery of a high therapeutic dose of temozolomide to tumor cells.
- Enhanced cytotoxicity observed against both glioma cells and, notably, glioma stem cells.
- Successful targeting of transferrin receptors on glioma cells.
Conclusions:
- Transferrin receptor-targeted nanoparticles offer a novel and effective strategy for delivering temozolomide to gliomas.
- This approach shows significant potential for overcoming treatment resistance and preventing tumor recurrence.
- The developed nanoparticles represent a promising therapeutic avenue for glioma, particularly those with specific genetic profiles like MGMT promoter methylation.
